Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p<0.001 (13.6% vs. 16.1%).
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5,047 (13.6%), control 3,923 of 24,404 (16.1%), NNT 40.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Shoaibi et al., 24 Sep 2020, retrospective, database analysis, USA, preprint, 5 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199463; this version posted September 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Title: Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
short title: Famotidine and risk of COVID-19 outcomes
Authors: Azza Shoaibi PhD, Stephen Fortin PharmD MS, Rachel Weinstein PhD, Jesse A. Berlin ScD,
Patrick Ryan PhD
Author
Azza Shoaibi
Email
ashoaibi@its.jnj.com
Position, department
Associate director, observational
health data analytics
Stephen Fortin
SFortin1@ITS.JNJ.com Manager, observational health
data analytics
Janssen Research & Development, LLC,
Titusville, NJ, USA
Rachel Weinstein
RWeinst1@its.jnj.com Senior director, consumer
epidemiology
Janssen Research & Development, LLC,
Titusville, NJ, USA
Jesse Berlin
JBerlin@its.jnj.com
Johnson & Johnson
Patrick Ryan
PRyan4@its.jnj.com
VP observational health data
analytics
VP, J&J epidemiology
Affiliation
Janssen Research & Development, LLC,
Titusville, NJ, USA
Janssen Research & Development, LLC,
Titusville, NJ, USA
Disclosures: AS, SF, RW, PBR are employees of Janssen Research and Development and shareholder of
Johnson & Johnson, the product manufacturer of famotidine. JB is an employee and shareholder of
Johnson & Johnson.
Abbreviations
Common Data Model
Confidence interval
Gastroesophageal reflux disease
hazard ratios
minimum detectible risk ratio
Observational Health and Data Sciences and Informatics
Observational Medical Outcomes Partnership
Premier Hospital Database (PHD
propensity score
proton pump inhibitors
standardized mean differences
CDM
CI
GERD
HRs
MDRR
OHDSI
OMOP
PHD
PS
PPI
SMD
Correspondence: Azza Shoaibi, MPH, PhD, 1125 Trenton-Harbourton Road, Titusville NJ, USA,
609 7302787, ashoaibi@its.jnj.com
Tel: +1
Author Contributions: All authors contributed to the conceptualization and design of the study. SF
authored the protocol of the study design, AS implemented the statistical analysis, RW, PBR and JB
reviewed and approved the study diagnostics and results. AS drafted the manuscript and all coauthors
reviewed and contributed to the manuscript writing.
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.09.23.20199463; this version posted September 24, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Abstract (260 words):
Background: Famotidine has been posited as a potential treatment for COVID-19. We compared the
incidence of COVID-19 outcomes (i.e., death; and death or intensive services use) among hospitalized
famotidine users vs. proton pump inhibitors (PPIs) users, hydroxychloroquine users or famotidine nonusers separately.
Methods: We constructed a retrospective cohort study using data from COVID-19 Premier Hospital
electronic health records. Study population were COVID-19 hospitalized patients aged 18 years or older.
Famotidine, PPI and hydroxychloroquine exposure groups were defined as patients dispensed any
medication containing one of..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit